Sam Waksal's ROCK2 biotech Graviton hauls in $35M boost from Enavate
Investors are pouring more money into a biotech created by industry veteran Sam Waksal, founder of ImClone Systems, Kadmon, MeiraGTx and Équilibre Biopharmaceuticals, and who has sold multiple companies to Big Pharma.
The latest bet, clinical-stage ROCK2 startup Graviton Bioscience, has landed an additional $35 million in funding, coming from lead investor Patient Square Capital’s Enavate Sciences, Waksal told Endpoints News on Thursday afternoon. He said the investment gives Graviton a higher valuation than during the biotech’s prior financings from Cormorant, Pontifax and other undisclosed backers, who had previously funded the company with at least $30 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.